Head and Neck Undifferentiated Carcinoma

subtype

Identifier: CI-CAN-00002838
Entity page: /cancer/head-and-neck-undifferentiated-carcinoma ↗
Edges: 110

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Head and Neck Undifferentiated Carcinoma approved for …APPROVED_FORderived4 of 4
← approved for	Dabrafenibsmall molecule FDA (US) · approved · 2023-03-16 · the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an F…	—	approved	Thyroid Gland Anaplastic Carcinoma	1	Regulatory	openfda	graph →
← approved for

Head and Neck Undifferentiated Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 39show all (up to 200)
→ investigated in trials for	Trametinibsmall molecule 7 trials (5 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 6 trials (3 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Dabrafenibsmall molecule 5 trials (4 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenvatinibsmall molecule 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Cemiplimabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Cobimetinibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Dabrafenib/Trametinib Regimen 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Pazopanibsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenib Tosylatesmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Vemurafenibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Head and Neck Undifferentiated Carcinoma	2	Observed	clinicaltrials	graph →

Head and Neck Undifferentiated Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 39show all (up to 200)

→ investigated in trials for

Trametinibsmall molecule

7 trials (5 active) · roll-up of the cancer and its descendants

—

Head and Neck Undifferentiated Carcinoma

Observed

Head and Neck Undifferentiated Carcinoma studied in …STUDIED_INderived10 of 67show all (up to 200)
→ studied in	NCT06814496Phase 1/Phase 2 · recruiting Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors · condition mapped ONTOLOGY_EXACT · 67 trials mapped (27 active)	—	—	Sinonasal Undifferentiated Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06176989Phase 2 · recruiting Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors · condition mapped CURATED_BROADER · 67 trials mapped (27 active)	—	—	Sinonasal Undifferentiated Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06235216Phase 2 · recruiting Sacituzumab govitEcan in THYroid Cancers · condition mapped ALIAS · 67 trials mapped (27 active)	—	—	Thyroid Gland Anaplastic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07181720Phase 1 · suspended CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · condition mapped ALIAS · 67 trials mapped (27 active)	—	—	Thyroid Gland Anaplastic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05557045Phase 1 · active not recruiting A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 · condition mapped ALIAS · 67 trials mapped (27 active)	—	—	Thyroid Gland Anaplastic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06902376Phase 1 · recruiting XL092 and Cemiplimab in BRAF WT Thyroid Cancer · condition mapped ALIAS · 67 trials mapped (27 active)	—	—	Thyroid Gland Anaplastic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07485569Phase 1 · active not recruiting Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · condition mapped ALIAS · 67 trials mapped (27 active)	—	—	Thyroid Gland Anaplastic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06940180Phase 2 · recruiting Toripalimab With Chemotherapy for Sinus Cancer · condition mapped ONTOLOGY_EXACT · 67 trials mapped (27 active)	—	—	Sinonasal Undifferentiated Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07440290Phase 2/Phase 3 · recruiting DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. · condition mapped ALIAS · 67 trials mapped (27 active)	—	—	Thyroid Gland Anaplastic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05453799Phase 2 · suspended Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer · condition mapped CURATED_BROADER · 67 trials mapped (27 active)	—	—	Thyroid Gland Anaplastic Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains